Jasper Therapeutics (NASDAQ:JSPR) Issues Earnings Results

Jasper Therapeutics (NASDAQ:JSPR) announced its quarterly earnings data on Monday. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12), Zacks reports.

Jasper Therapeutics Price Performance

JSPR traded up $0.08 on Monday, reaching $1.86. 239,392 shares of the stock were exchanged, compared to its average volume of 465,601. The company’s 50-day moving average price is $2.41 and its 200 day moving average price is $3.66. Jasper Therapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $26.05. The firm has a market capitalization of $30.14 million, a PE ratio of -0.31 and a beta of 2.83.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on JSPR shares. JMP Securities dropped their target price on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a report on Monday, September 22nd. UBS Group decreased their target price on shares of Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, August 15th. BTIG Research lowered their target price on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Evercore ISI reduced their price target on shares of Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a research note on Monday, September 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $25.63.

Insiders Place Their Bets

In other Jasper Therapeutics news, Director Judith Anne Shizuru acquired 41,000 shares of the business’s stock in a transaction on Monday, September 22nd. The stock was bought at an average price of $2.43 per share, for a total transaction of $99,630.00. Following the acquisition, the director owned 156,901 shares in the company, valued at approximately $381,269.43. The trade was a 35.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Svetlana Lucas bought 20,000 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was bought at an average price of $2.43 per share, with a total value of $48,600.00. Following the completion of the acquisition, the director owned 20,000 shares in the company, valued at $48,600. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought 143,000 shares of company stock worth $347,490 in the last 90 days. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Jasper Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics during the 1st quarter worth $46,000. Engineers Gate Manager LP acquired a new position in Jasper Therapeutics during the second quarter worth about $78,000. Goldman Sachs Group Inc. grew its position in shares of Jasper Therapeutics by 11.2% in the first quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock valued at $1,005,000 after purchasing an additional 23,453 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Jasper Therapeutics in the second quarter valued at approximately $152,000. Finally, Marshall Wace LLP acquired a new position in shares of Jasper Therapeutics during the 2nd quarter worth approximately $281,000. 79.85% of the stock is owned by hedge funds and other institutional investors.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.